-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As of January 4, 2021, the global pandemic of neo-crown pneumonia has infected more than 83 million people and killed more than 1 million.
epidemiology, clinical characteristics, pathogenesis and complications of patients in the acute phase of Covid-19 have been fully studied, but after the patient recovers, the long-term follow-up study has not been carried out systematically.
researchers recently studied the long-term health outcomes of patients who had been discharged from hospital with Covid-19 to examine the effects of associated risk factors, especially the severity of the disease, on the long-term prognostication of patients.
researchers conducted a two-way cohort study of Covid-19 patients discharged from Jinyintan Hospital (Wuhan, China) between January 7, 2020 and May 29, 2020.
all patients were subjected to a series of questionnaires to assess their symptoms and health-related quality of life, with physical examinations, six-minute walking tests and blood tests.
According to the severity of the patient's condition during hospitalization, the patients were divided into 7 levels (1-7, 1 lowest, 7 on behalf of patient death), and patients at levels 3, 4 and 5-6 were randomly sampled for lung function tests, chest CT and ultrasound.
patients who participated in the SARS-Cov-2 trial of Lopinave were tested for severe acute respiratory syndrome coronavirus 2 antibody testing.
the relationship between disease severity and long-term health prognosmation was assessed using a multivariable adjustment linear or logical regression model.
1733 patients discharged from hospital with neo-crown pneumonia participated in the study, with an average age of 57.0 years and 897 men, and the study was conducted from 16 June 2020 to 3 September 2020, with an average discharge time of 186.0 days.
, the most common abnormal symptoms were fatigue or fatigue (63%, 1038 cases) and difficulty sleeping (26%, 437), and 23% of patients recovered from depression or anxiety (437 cases).
24% of patients with a grade 3 severity of the disease, the average distance from the six-minute walking test after rehabilitation was lower than the average, with 22% of patients with level 4 and 29% of patients with grades 5-6.
CT scores were 3.0 for patients with level 3 severity of the disease, 4.0 for patients with level 4 and 5.0 for patients with level 5-6.
multi-factor adjustment, the risk of pulmonary dispersal dysfunction in patients with level 4 was 1.61, 5-6 and 4.60 compared to patients with a level 3 disease level.
the risk ratio of depression or anxiety in patients with level 4 was 0.88 and in patients with level 5-6 it was 1.77 compared to patients with a grade 3 severity of the disease.
the risk ratio of fatigue or fatigue in level 4 patients was 0.74 and 2.69 in patients with level 5-6 compared to patients with a grade 3 severity of the disease.
94 patients were tested for serum antibodies, and the serum-positive rate (96.2% vs 58.5%) and average titration (19.0 vs 10.0) were significantly lower than in the acute phase.
822 patients did not have acute kidney injury, and in patients with acute cystic filtration rates greater than 90 mL/min/1.73 m2, the rate of renal cystic filtration decreased during follow-up.
study found that six months after the recovery of patients with neo-coronary pneumonia, most patients will continue to show symptoms such as fatigue, fatigue, sleep difficulties and anxiety, seriously impaired lung dispersal function during hospitalization, chest imaging abnormalities.
。